Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Metz

Showing results (1-10 of 256) with videos related to

Pageof 26
Sort By:
The British Journal of Dermatology|March 26, 2026
JAK inhibition, a potential novel mechanism for the treatment of chronic spontaneous urticariaMartin Metz
Journal of the European Academy of Dermatology and Venereology : JEADV|February 25, 2025
No allergy, but mast cells are involved: MRGPRX2 in chronic inflammatory skin diseasesMartin Metz
The New England Journal of Medicine|October 27, 2023
Targeting Interleukin-31 in PrurigoMartin Metz
Experimental Dermatology|July 17, 2019
Treatments for chronic pruritus outside of the boxMartin Metz
Current Problems in Dermatology|September 1, 2016
Itch Management: Topical AgentsMartin Metz, Petra Staubach
Current Opinion in Immunology|October 16, 2009
Innate immunity and allergy in the skinMartin Metz, Marcus Maurer
Allergologie Select|February 22, 2021
Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy?Martin Metz, Marcus Maurer
Experimental Dermatology|November 9, 2005
The status quo and quo vadis of mast cellsMarcus Maurer, Martin Metz
Expert Review of Clinical Immunology|December 18, 2010
Rupatadine for the treatment of allergic rhinitis and urticariaMartin Metz, Marcus Maurer
Trends in Immunology|April 3, 2007
Mast cells--key effector cells in immune responsesMartin Metz, Marcus Maurer
Pageof 26

Showing results (1-10 of 256) with videos related to

Sort By:
Pageof 26
The British Journal of Dermatology|March 26, 2026
JAK inhibition, a potential novel mechanism for the treatment of chronic spontaneous urticariaMartin Metz
Journal of the European Academy of Dermatology and Venereology : JEADV|February 25, 2025
No allergy, but mast cells are involved: MRGPRX2 in chronic inflammatory skin diseasesMartin Metz
The New England Journal of Medicine|October 27, 2023
Targeting Interleukin-31 in PrurigoMartin Metz
Experimental Dermatology|July 17, 2019
Treatments for chronic pruritus outside of the boxMartin Metz
Current Problems in Dermatology|September 1, 2016
Itch Management: Topical AgentsMartin Metz, Petra Staubach
Current Opinion in Immunology|October 16, 2009
Innate immunity and allergy in the skinMartin Metz, Marcus Maurer
Allergologie Select|February 22, 2021
Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy?Martin Metz, Marcus Maurer
Experimental Dermatology|November 9, 2005
The status quo and quo vadis of mast cellsMarcus Maurer, Martin Metz
Expert Review of Clinical Immunology|December 18, 2010
Rupatadine for the treatment of allergic rhinitis and urticariaMartin Metz, Marcus Maurer
Trends in Immunology|April 3, 2007
Mast cells--key effector cells in immune responsesMartin Metz, Marcus Maurer
Pageof 26